We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Noah Hahn

Noah M Hahn MD

Associate Professor of Medicine, Departments of Oncology and Urology; Director, Medical Oncology Bladder Cancer Program, Johns Hopkins School of Medicine; Johns Hopkins Greenberg Bladder Cancer Institute, Baltimore, Maryland

Noah M. Hahn, MD joined the Johns Hopkins University School of Medicine faculty in April 2014 as the director of the medical oncology bladder cancer program with the academic rank of associate professor of oncology and urology.   He serves as the bladder cancer chairman of the Eastern Cooperative Oncology Group (ECOG), co-chairs the Hoosier Cancer Research Network genitourinary oncology clinical trials working group, participates on the NCI Bladder Cancer Task Force, and serves on the scientific advisory board of the Bladder Cancer Advocacy Network.  Dr. Hahn’s clinical and translational research interests focus on improving outcomes for patients with bladder and prostate cancer through: 1) The identification and validation of predictive biomarkers relevant to GU cancers, and 2) The identification of novel therapeutic and preventative targets for GU cancer patients.  Dr. Hahn and his wife Molly are relocating to Baltimore, Maryland with their three children: Doyle (age 6), Leo (age 4), and Elizabeth (age 2).

Disclosures

Consulting – OncoGeneX, Merck

Honoraria – Medivation

Research support to institution – Merck, Abbott, Sanofi, Millennium, BMS, Genentech, Novartis, Celgene, OncoGeneX